Modulation of PAR1 signalling by benzimidazole compounds

British Journal of Pharmacology

Volumn 167, Issue 1, 2012, Pages 80-94

  Asteriti, S ^a   Daniele, S ^a   Porchia, F ^a   Dell Anno, M T ^a   Fazzini, A ^a   Pugliesi, I ^a   Trincavelli, M L ^a   Taliani, S ^a   Martini, C ^a   Mazzoni, M R ^a   Gilchrist, A ^b  

^a UNIVERSITY OF PISA   (Italy)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

allosteric; benzimidazole scaffold; biased signalling; endothelial cells; functional selectivity; G ; GPCR; HMEC 1; PAR1; positive negative modulation; protease activated receptor; Q94; thrombin; thrombin receptor

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; CALCIUM ION; CYCLIC AMP; FORSKOLIN; INOSITOL 1,4,5 TRISPHOSPHATE; ISOPRENALINE; PEPTIDE DERIVATIVE; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 1 AGONIST; PROTEINASE ACTIVATED RECEPTOR 2; Q 109; Q 89; Q 94; RECEPTOR SPECIFIC ACTIVATING PEPTIDE; THROMBIN; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BIOACCUMULATION; BIOSYNTHESIS; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; MICROVASCULAR ENDOTHELIAL CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BENZIMIDAZOLES; CALCIUM; CELL LINE; CYCLIC AMP; FORSKOLIN; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE; ISOPROTERENOL; RECEPTOR, PAR-1; SIGNAL TRANSDUCTION;

EID: 84864685414     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01974.x     Document Type: Article

References (42)

1. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, et al,. (1992). HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99: 683-690.
2. Ahn HS, Foster C, Boykow G, Stamford A, Manna M, Graziano M, (2000). Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1- methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol 60: 1425-1434.
3. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
4. 12, and β-arrestin 1. FASEB J 24: 3522-3535.
5. Barr AJ, Brass LF, Manning DR, (1997). Reconstitution of receptors and GTP-binding regulatory proteins (G proteins) in Sf9 cells. A direct evaluation of selectivity in receptor.G protein coupling. J Biol Chem 272: 2223-2229.
6. Chackalamannil S, (2006). Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. J Med Chem 49: 5389-5403.
7. Chackalamannil S, Doller D, Eagen K, Czarniecki M, Ahn HS, Foster CJ, et al,. (2001). Potent, low molecular weight thrombin receptor antagonists. Bioorg Med Chem Lett 11: 2851-2853.
8. Chackalamannil S, Xia Y, Greenlee WJ, Clasby M, Doller D, Tsai H, et al,. (2005). Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J Med Chem 48: 5884-5887.
9. Christopoulos A, Kenakin T, (2002). G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323-374.
10. 3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. J Med Chem 52: 2407-2419.
11. Coughlin SR, (2001). Protease-activated receptors in vascular biology. Thromb Haemost 86: 298-307.
12. Covic L, Gresser AL, Talavera J, Swift S, Kuliopulos A, (2002a). Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci USA 99: 643-648.
13. Covic L, Misra M, Badar J, Singh C, Kuliopulos A, (2002b). Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 8: 1161-1165.
14. q and cooperation between ERK1/2 and Rho kinase signaling pathways. Mol Biol Cell 19: 2520-2533.
15. Dietrich A, Kalwa H, Gudermann T, (2010). TRPC channels in vascular cell function. Thromb Haemost 103: 262-270.
16. 1. Proc Natl Acad Sci USA 108: 2951-2956.
17. Ehlert FJ, (2005). Analysis of allosterism in functional assays. J Pharmacol Exp Ther 315: 740-754.
18. 4 induces a distinct actin fiber formation via p38 MAPK in human lung endothelial cells. J Histochem Cytochem 53: 1121-1129.
19. Gerwins P, (1993). Modification of a competitive protein binding assay for determination of inositol 1,4,5-trisphosphate. Anal Biochem 210: 45-49.
20. Gilchrist A, Vanhauwe JF, Li A, Thomas TO, Voyno-Yasenetskaya T, Hamm HE, (2001). Gα minigenes expressing C-terminal peptides serve as specific inhibitor s of thrombin-mediated endothelial activation. J Biol Chem 276: 25672-25679.
21. 4 mediates endothelium-dependent relaxation to thrombin and trypsin in human pulmonary arteries. J Cardiovasc Pharmacol 38: 108-119.
22. Hamilton JR, Moffatt JD, Tatoulis J, Cocks TM, (2002). Enzymatic activation of endothelial protease-activated receptors is dependent on artery diameter in human and porcine isolated coronary arteries. Br J Pharmacol 136: 492-501.
23. 4) in vascular endothelial cells. J Pharmacol Exp Ther 322: 668-677.
24. Hollenberg MD, Compton SJ, (2002). International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 54: 203-217.
25. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR, (1999). Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103: 879-887.
26. Kenakin T, Miller LJ, (2010). Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62: 265-304.
27. Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, Kodra JT, et al,. (2007). Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci USA 104: 937-942.
28. Luo W, Wang Y, Reiser G, (2007). Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res Rev 56: 331-345.
29. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R, (2001). Proteinase-activated receptors. Pharmacol Rev 53: 245-282.
30. McLaughlin JN, Shen L, Holinstat M, Brooks JD, Dibenedetto E, Hamm HE, (2005). Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease-activated receptor-1. J Biol Chem 280: 25048-25059.
31. Nordstedt C, Fredholm BB, (1990). A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. Anal Biochem 189: 231-234.
32. Nystedt S, Emilsson K, Larsson AK, Strömbeck B, Sundelin J, (1995). Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur J Biochem 232: 84-89.
33. 1. J Biol Chem 275: 13502-13509.
34. Ramachandran R, Hollenberg MD, (2008). Proteinases and signaling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 153: S263-S282.
35. Ramachandran R, Mihara K, Mathur M, Rochdi MD, Bouvier M, Defea K, et al,. (2009). Agonist-biased signaling via proteinase activated receptor-2: differential activation of calcium and mitogen-activated protein kinase pathways. Mol Pharmacol 76: 791-801.
36. Robin J, Kharbanda R, Mclean P, Campbell R, Vallance P, (2003). Protease-activated receptor 2-mediated vasodilatation in humans in vivo: role of nitric oxide and prostanoids. Circulation 107: 954-959.
37. Russo A, Soh UJ, Trejo J, (2009). Proteases display biased agonism at protease-activated receptors: location matters! Mol Interv 9: 87-96.
38. Scotton CJ, Krupiczojc MA, Königshoff M, Mercer PF, Lee YC, Kaminski N, et al,. (2009). Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 119: 2550-2563.
39. Sugunaraj JP, Mehta V, Kalra A, Sukhija R, Palaniswamy C, (2011). Protease-Activated Receptor-1 Antagonists: focus on SCH 530348. Am J Ther Jan 18. DOI: 10.1097/MJT.0b013e3181ff7c16 [Epub ahead of print].
40. Vandenbroucke E, Mehta D, Minshall E, Malik AB, (2008). Regulation of endothelial junctional permeability. Ann NY Acad Sci 1123: 134-145.
41. o proteins in endothelial cells to regulate intracellular calcium and cell shape changes. J Biol Chem 277: 34143-34149.
42. Wang L, Martin B, Brenneman R, Luttrell LM, Maudsley S, (2009). Allosteric modulators of G protein-coupled receptors: future therapeutics for complex physiological disorders. J Pharmacol Exp Ther 331: 340-348.